Provided by Tiger Trade Technology Pte. Ltd.

IGC Pharma

0.2504
+0.00200.81%
Post-market: 0.25970.0093+3.71%19:59 EST
Volume:438.45K
Turnover:109.22K
Market Cap:23.80M
PE:-3.21
High:0.2599
Open:0.2470
Low:0.2420
Close:0.2484
52wk High:0.4985
52wk Low:0.2420
Shares:95.04M
Float Shares:87.50M
Volume Ratio:0.92
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0780
EPS(LYR):-0.0931
ROE:-83.34%
ROA:-50.31%
PB:2.94
PE(LYR):-2.69

Loading ...

IGC Pharma reaches 70% enrollment in Phase 2 CALMA trial of IGC-AD1

TIPRANKS
·
Feb 02

IGC Pharma Nears Full Enrollment in Phase 2 Trial of IGC-AD1 for Alzheimer's Agitation

Reuters
·
Feb 02

TOWNPLACE, SHKP's Premium Residential Leasing Brand - The First in Hong Kong to Reward You with The Point

prnewswire
·
Feb 02

IGC Pharma expands Phase 2 CALMA trial with new clinical site

TIPRANKS
·
Jan 22

IGC Pharma Inc - Files Prospectus Related to Offering of 779,997 Shares of Common Stock

THOMSON REUTERS
·
Jan 06

IGC Pharma Secures U.S. Patent for Microdose Cannabinoid Treatment of Stuttering and Tourette's Syndrome

Reuters
·
Dec 19, 2025

IGC Pharma Inc - Increases Authorized Common Stock to 600 Mln Shares - SEC Filing

THOMSON REUTERS
·
Dec 16, 2025

IGC Pharma Quadruples Authorized Common Shares to 600 Million

Reuters
·
Dec 16, 2025

Ascendiant Capital Markets Raises IGC Pharma Price Target to $4.75

Reuters
·
Dec 10, 2025

IGC Pharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 10, 2025

IGC Pharma Reaches 65% Enrollment in Phase 2 CALMA Trial for Alzheimer’s Agitation

Reuters
·
Dec 09, 2025

Press Release: NeoVolta Enters into Definitive Agreements Led by Infinite Grid Capital to Advance 2 GWh U.S. Battery Energy Storage System Manufacturing Initiative

Dow Jones
·
Nov 24, 2025

IGC Pharma Reports Progress Amid Financial Losses

TIPRANKS
·
Nov 18, 2025

IGC Pharma expects ‘continued strong momentum’ into 2H26

TIPRANKS
·
Nov 17, 2025

IGC Pharma Q2 EPS $(0.02), Inline, Sales $191.000K Miss $325.000K Estimate

Benzinga
·
Nov 17, 2025

IGC Pharma Sells Non-Core Facility for $2.7 Million

Reuters
·
Nov 17, 2025

IGC Pharma files to sell 978,235 shares of common stock for holders

TIPRANKS
·
Nov 17, 2025

IGC Pharma Reports Lower Revenue Amid Shift to Alzheimer’s Drug Development

Reuters
·
Nov 15, 2025

IGC Pharma Sells Vancouver Assets to Wellness Essentials

TIPRANKS
·
Nov 14, 2025

IGC Pharma Granted U.S. Patent for Novel Alzheimer's Drug Composition Targeting CNS Disorders

Reuters
·
Nov 13, 2025